Autoimmune Disease Diagnosis Market Size & Share - Growth Analysis and Forecast 2026-2035

Autoimmune Disease Diagnosis Market - Regional Analysis

North America Market Insights

North America autoimmune disease diagnosis market is projected to account for the highest share of 38.4% during the forecast period. The region’s leadership is mainly propelled by high public awareness, proactive patient screening, and a well-established healthcare infrastructure. The region also benefits from a robust pipeline of R&D, particularly in the integration of artificial intelligence and high-throughput multiplex testing platforms that streamline laboratory workflows. In January 2025, a study by Mayo Clinic found that around 15 million people in the U.S., which is 4.6% of the population, have at least one of 105 autoimmune diseases, with women representing the majority of cases. The research identified rheumatoid arthritis, psoriasis, type 1 diabetes, Graves’ disease, and autoimmune thyroiditis as the most prevalent autoimmune conditions, thus heightening the demand for suitable diagnostics.

The strong technological adoption, with clinical laboratories increasingly integrating artificial intelligence and advanced multiplex testing, is the main factor uplifting the U.S. autoimmune disease diagnosis market. Considerable funding from public institutions, supportive commercial insurance frameworks, and strategic collaborations between diagnostic developers and biopharmaceutical firms for companion diagnostics accelerate product commercialization. As stated by NIH in June 2025, it is promoting research to advance understanding of autoimmune diseases by integrating genetic, environmental, and immunological factors to improve diagnosis and treatment. This initiative is highly focused on identifying disease drivers, biomarkers, predictive models, and new technologies to detect and manage autoimmunity earlier. It also encourages collaborative research on preclinical autoimmunity, thus making it suitable for standard market growth.

In Canada, the market has been showcasing noteworthy expansion supported by provincial health insurance plans that facilitate patient access to diagnostic testing. The market is also being driven by a rising prevalence of chronic conditions and an increasing clinical focus on early disease intervention to manage long-term healthcare costs. For instance, based on government data published in September 2023, Ontario’s 2023-24 Community Access Pilot expanded access to autoimmune diagnostic testing by adding ANCA and ACPA (Anti-CCP) tests at no cost through community laboratories. It mentions that ANCA testing supports the diagnosis of serious ANCA-associated vasculitis, whereas ACPA testing improves detection and prediction of rheumatoid arthritis outcomes, thus elevating the growth potential of the market.

APAC Market Insights

Asia Pacific market is anticipated to grow at the fastest rate from 2026 to 2035. The region’s prominence in this field is mainly propelled by rapidly modernizing healthcare infrastructures, expanding medical tourism, and rising disposable incomes across emerging economies. Market expansion is also fueled by a massive, aging patient pool and a surging prevalence of chronic conditions, which are linked to urbanization, changing dietary habits, and environmental shifts.  In this context, Singapore General Hospital in May 2025 reported that it is leading a USD 5.77 million, five-year research project to improve diagnosis and treatment of systemic sclerosis, which is a rare and life-threatening autoimmune disease. The Singapore Systemic Sclerosis Precision Medicine Project (Sysmic) will analyze genetic, immune, and imaging data from about 300 patients with the main goal of developing predictive algorithms and personalized therapies.

Extensive healthcare infrastructure modernization under national health initiatives is responsibly driving the autoimmune disease diagnosis market in China. In addition, strong government backing for precision medicine, substantial domestic venture capital funding, and a shifting clinical focus toward early disease intervention remarkably accelerate market demand. In August 2024, Filipino and China-based researchers announced the development of a rapid, minimally invasive diagnostic tool for autoimmune diseases such as arthritis and lupus. This technology uses blood samples and peptide science to identify disease biomarkers, thereby offering faster results when compared with traditional biopsy-based methods, thus suitable for bolstering the country’s market.

In India, the market is experiencing exponential growth, which is driven by rising disposable incomes and the rapid expansion of private diagnostic laboratory networks into Tier 2 and Tier 3 cities. To handle soaring testing volumes cost-effectively, domestic laboratories are making a shift from traditional manual testing to high-throughput automated immunoassay and multiplex platforms. In addition, supportive government healthcare initiatives, a booming medical tourism sector, and rising investments from global diagnostic giants are significantly accelerating market penetration across the country. For instance, Thyrocare Technologies Limited in August 2024 entered into an agreement to acquire the diagnostic and pathological services business of Vimta Labs to expand its healthcare diagnostics footprint. This move provides access to 11 diagnostic centers across multiple states in the country, which include an NABL-accredited central laboratory in Hyderabad, thus enhancing the delivery of affordable, high-quality diagnostic services.

Europe Market Insights

The Europe market is expected to expand notably during the forecast period. The region’s prominence in this field is mainly propelled by highly sophisticated healthcare systems, public health insurance coverage, and strong clinical emphasis on early disease management. The region’s clinical laboratories are at the forefront of adopting technologies, integrating artificial intelligence for pattern recognition and automated, high-throughput multiplex assays to streamline heavy workflows.  Werfen in February 2024 announced that it received CE Mark approval for its Aptiva® APS IgG and IgM reagents, which allow earlier and more accurate diagnosis of antiphospholipid syndrome, a complex autoimmune disease. This fully automated Aptiva platform uses particle-based multi-analyte technology to deliver high-throughput testing and improve laboratory efficiency.

The comprehensive statutory health insurance coverage and a strong clinical emphasis in terms of precision medicine are deliberately propelling the growth of the market in Germany. The substantial federal funding for biomarker research and strong local manufacturing capabilities from leading medical technology firms solidify Germany's prominent position in the regional landscape. In this context, Germany in November 2025 launched a USD 540 million national decade against post-infectious diseases to advance research into ME/CFS and post-viral autoimmune diseases. This particular initiative will fund research on disease mechanisms, diagnostics, biomarkers, clinical trials, genome sequencing, AI-based analysis, and the creation of a national patient database.

The UK autoimmune disease diagnosis market is gaining enhanced traction, which is propelled by a well-established National Health Service (NHS) infrastructure and a strong clinical focus on early disease intervention to manage long-term public healthcare expenditures. The country also benefits from substantial funding from UK Research and Innovation, active academic-corporate partnerships for biomarker discovery, and a growing domestic pipeline for companion diagnostics. In May 2025, the UK Medical Research Council announced the launch of the infections and immunity research grant opportunity with the main goal of supporting innovative projects investigating interactions between infectious agents and the immune system. This programme allows eligible researchers to apply for funding of up to five years, which covers collaborative studies that advance understanding of immunity, disease mechanisms, and potential interventions.